Rexahn Pharmaceuticals Presents Clinical Trial Results for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the 2016 American Association for Cancer Research Annual Meeting

Data Featured at Late Breaking and Clinical Trials Session Suggest Potential Dose and Time Dependent Clinical Benefit of Archexin ® in Combination with Everolimus

Additional Poster Presentations on RX-3117 and Archexin ® -Nano Also Showcased

ROCKVILLE, Md., April 20, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that final data from the dose-escalation segment (Stage 1) of a Phase Ib/IIa clinical trial of Archexin ® were presented at the 2016 American Association for Cancer Research Annual Meeting (AACR) in New Orleans, Louisiana. 

The Phase Ib/IIa clinical trial is evaluating Archexin, in combination with everolimus (a widely used chemotherapy drug) in patients with metastatic renal cell carcinoma (mRCC).  The results were presented during the Late Breaking and Clinical Trials Session at AACR by Drs. S. Tagawa, G. Chatta, N. Agarwal and Rexahn scientists in a poster presentation entitled “Phase Ib/IIa Study of RX-0201 (Archexin ® ), A Novel Akt-1 Antisense Combined with Everolimus to Treat Metastatic Clear Cell Renal Carcinoma.”

“The results from the Archexin dose escalation clinical study are promising and offer an early signal of the potential safety and clinical activity of Archexin in combination with everolimus,” commented Scott Tagawa, MD, MS, Medical Director of the Genitourinary Oncology Research Program at Weill Cornell Medicine.  “The combination of Archexin and everolimus is rational based upon potential complementary mechanisms of action.  While the primary objective of the initial dose escalation phase of the study was not intended to provide an efficacy evaluation, we nevertheless observed evidence of stable disease and tumor burden reduction in a significant number of patients in the study.  When you consider that these are patients with very advanced disease, who have stopped responding to other therapies, we believe these data are especially encouraging.”

Archexin Phase Ib/IIa Clinical Data

The results from Stage 1 of the Phase Ib/IIa study presented at AACR showed that in mRCC patients that have previously received multiple anti-cancer therapies, Archexin treatment produced both stable disease (which persisted for up to 383 days) and a reduction in tumor burden.  Compared to baseline CT scans, three patients experienced reductions in the size of their tumors of up to 36%.  At the lowest dose level of Archexin administered (125 mg/m 2 /day) one patient had a 16% tumor reduction after four cycles of treatment.  At the second dose level (200 mg/m 2 /day) one patient experienced a 36% tumor reduction after two cycles of treatment.  At the highest dose level (250 mg/m 2 /day), which has been determined to be the maximum tolerated dose, one patient had a 32% tumor reduction following six cycles of treatment.

In the present study Archexin appeared to be safe and well tolerated at each of the dose levels tested with no dose limiting adverse events.  The most commonly reported adverse event in patients taking the combination of Archexin and everolimus was thrombocytopenia.

“The emerging clinical data from our Archexin program suggest a potentially unique profile in metastatic renal cell carcinoma with both a dose and time dependent clinical benefit,” said Dr. Ely Benaim, Chief Medical Officer for Rexahn.  “Based on these encouraging results, and our identification of a maximum tolerated dose, Rexahn has commenced enrollment in the second part of the study, which is a randomized, open-label, two-arm dose expansion study to further evaluate the safety and efficacy of Archexin in combination with everolimus, versus everolimus alone.  We look forward to the possibility of confirming these results in the randomized part of the study.”

The second part (Stage 2) of the Phase Ib/IIa study will enroll up to 30 patients with mRCC who will be randomized to receive either Archexin in combination with everolimus, or everolimus alone, in a ratio of 2:1.  The maximum tolerated dose of 250 mg/m 2 /day of Archexin – identified in Stage 1, will be administered along with 10 mg of everolimus, versus 10 mg everolimus alone.

The primary endpoint in Stage 2 of the Phase Ib/IIa clinical trial is the percentage of progression free patients following eight cycles of therapy. Patients are scanned (CT or MRI) for the assessment of tumor progression after every two cycles of therapy.  Secondary endpoints include pharmacokinetic profile, incidence of adverse events, changes in clinical laboratory tests and vital signs over time, tumor response, duration of response, time to response, and response rate. Exploratory endpoints include blood levels of Akt pathway biomarkers, tumor apoptosis biomarkers, or other relevant biomarkers.

Additional Poster Presentations at AACR

Rexahn scientists and their collaborators also presented two additional posters detailing advancements in the Company’s RX-3117 and Archexin-Nano programs. 

In a poster presentation entitled “Inhibition of DNA Methyltransferase by RX-3117 Leads to Upregulation of Hypomethylated Targets,” Rexahn scientists presented new preclinical data further describing the novel mechanism of action of RX-3117, an orally bioavailable, small molecule, investigational anti-cancer therapy that targets a unique biological pathway implicated in the development and metastasis of numerous cancers. 

In a separate poster presentation entitled “Folate Receptor-Targeted Lipid Coated Albumin Nanoparticles (F-LCAN) for Therapeutic Delivery of RX-0201 (Archexin), An Antisense Oligonucleotide against Akt-1,” preclinical study results of a nanoparticle-Archexin combination under development by Rexahn (Archexin-Nano) were presented.  Preclinical results from in vitro cell studies, pharmacokinetic and biodistribution studies and in vivo xenograft efficacy studies showed increased potency and a prolonged duration of action for Archexin-nano, suggesting that the F-LCAN formulation could be an effective formulation for therapeutic delivery of antisense agents such as Archexin.

About Archexin® Archexin is a unique antisense drug candidate that specifically inhibits the cancer cell signaling protein Akt-1. Archexin is the only specific inhibitor of Akt-1 in clinical development. The activated form of Akt-1, which is involved in cancer cell growth, survival, angiogenesis, and drug resistance, has been shown to be present or elevated in more than 12 different human cancer cell lines, including pancreatic and renal cell carcinoma. By inhibiting Akt-1, Archexin has been shown to both inhibit the growth of renal cell carcinoma cell lines and exhibit a longer survival benefit in the human renal cell carcinoma animal xenograft model. Thus, while Akt-1 is a very specific anti-cancer target, it may have broad therapeutic potential across multiple types of cancer.

Archexin has completed a Phase I clinical trial in cancer patients with solid tumors and was shown to be safe and well tolerated. The dose-limiting toxicity was Grade 3 fatigue. In a small Phase IIa trial in advanced pancreatic cancer patients, Archexin in combination with gemcitabine was shown to be safe and well tolerated and showed a preliminary efficacy signal with a median survival of 9.1 months in evaluable patients.

Metastatic RCC represents an attractive market opportunity with an estimated annual incidence of 90,000 patients worldwide. Metastatic RCC patients receiving standard of care treatment have a poor prognosis with an overall survival of less than two years. Rexahn has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for Archexin for metastatic RCC as well as four other cancers.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer.  The Company’s mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies indicate that certain of Rexahn’s product candidates may be effective against multiple types of cancer, drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments.  The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: Supinoxin; RX-3117; and Archexin ® , and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies.  For more information about the Company and its oncology programs, please visit  www.rexahn.com .

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, enrollments in clinical trials, the path of clinical trials and development activities, anticipated market sizes, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, understandings and beliefs regarding the role of certain biological mechanisms and processes in cancer; drug candidates being in early stages of development, including in pre-clinical development; the ability to initially develop drug candidates for orphan indications to reduce the time-to-market and take advantage of certain incentives provided by the U.S. Food and Drug Administration; and the ability to transition from our initial focus on developing drug candidates for orphan indications to candidates for more highly prevalent indications. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Stacey Jurchison Rexahn Investor Relations 240-268-5300 x 324 Jurchisons@rexahn.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 360

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 519

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 55

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 349

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 113

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 328

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading

Top 5 Most Recently Viewed Articles

Venezuela's Political Shift and Its Impact on Global Oil Markets

Updated Category News Views 122

Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....

Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative

Updated Category News Views 27

The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...

Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement

Updated Category News Views 74

DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...

Continue Reading
Insights into the Growth of the Global Fondant Market Trends

Updated Category News Views 230

Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...

Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details

Updated Category News Views 110

Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...

Continue Reading